NLRP3 inflammasome activation is required for fibrosis development in NAFLD

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†

Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791

Pattern Recognition Receptors and Inflammation

Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895

The Inflammasome

Martinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.

MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345

Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults

Vernon, G. C., Baranova, A. V., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,116

The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study

Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890

The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance

Vandanmagsar, B., Youm, Y.-H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., Ravussin, E., Stephens, J. M., & Dixit, V. D. (2011) · Nature Medicine · doi:10.1038/nm.2279 · Cited by 2,655

Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis

Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548

Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity

Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435

Fatty acid–induced NLRP3-ASC inflammasome activation interferes with insulin signaling

Wen, H., Gris, D., Lei, Y., Jha, S., Zhang, L., Huang, M. T.-H., Brickey, W. J., & Ting, J. P.-Y. (2011) · Nature Immunology · doi:10.1038/ni.2022 · Cited by 1,698

NLRP6 Plays an Important Role in Early Hepatic Immunopathology Caused by Schistosoma mansoni Infection

Sanches, R. C. O., Souza, C. D. L. R., Marinho, F. V., Mambelli, F., Morais, S. B., Guimarães, E. S., & Oliveira, S. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00795 · Cited by 18

Regulatory Role and Biomarker Potential of Gut Microbiota Metabolites in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease to Hepatocellular Carcinoma

Che, Z., Xue, W., Zhao, X., Hu, C., & Tian, Y. (2025) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000914 · Cited by 20

A combined association of serum uric acid, alanine aminotransferase and waist circumference with non-alcoholic fatty liver disease: a community-based study

Wang, M., Wang, M., Zhang, R., Zhang, L., Ding, Y., Tang, Z., Fan, H., Wang, H., Zhang, W., Chen, Y., et al. (2022) · PeerJ · doi:10.7717/peerj.13022 · Cited by 18

NLRP3 ‐directed antisense oligonucleotides reduce microglial immunoactivities in vitro

Braatz, C., Komes, M. P., Ravichandran, K. A., de Fragas, M. G., Griep, A., Schwartz, S., McManus, R. M., & Heneka, M. T. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15778 · Cited by 20

Honey vesicle-like nanoparticles protect aged liver from non-alcoholic steatohepatitis

Liu, B., Nguyen, P. L., Yu, H., Li, X., Wang, H., Nguyen, T. G. B., Sahoo, P. K., Sur, M., Reddy, J., Sillman, S. J., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.05.002 · Cited by 20

Cell death mechanisms in human chronic liver diseases: a far cry from clinical applicability

Mazzolini, G. D., Sowa, J., & Canbay, A. E. (2016) · Clinical Science · doi:10.1042/cs20160035 · Cited by 18

Transcription factor binding site enrichment analysis predicts drivers of altered gene expression in nonalcoholic steatohepatitis

Lake, A. D., Chaput, A., Novák, P., Cherrington, N. J., & Smith, C. L. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.006 · Cited by 19

Sterile inflammation in MASH: emerging role of extracellular RNA and therapeutic strategies

Raza, S., Mahamood, R., Medhe, P., Shahi, A., Yadav, A., Tewari, A., & Sinha, R. A. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00083-0 · Cited by 21

Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs

Galatou, E., Mourelatou, E. A., Hatziantoniou, S., & Vizirianakis, I. S. (2022) · Antioxidants · doi:10.3390/antiox11061060 · Cited by 18

Verapamil-loaded supramolecular hydrogel patch attenuates metabolic dysfunction-associated fatty liver disease via restoration of autophagic clearance of aggregated proteins and inhibition of NLRP3

Kim, D. K., Han, D., Bae, J., Kim, H., Lee, S., Kim, J.-S., Jeong, Y., Shin, J., & Park, H. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00342-5 · Cited by 18

Emerging Links between Nonalcoholic Fatty Liver Disease and Neurodegeneration

Kelty, T. J., Dashek, R. J., Arnold, W. D., & Rector, R. S. (2023) · Seminars in Liver Disease · doi:10.1055/s-0043-1762585 · Cited by 19

Tryptanthrin suppresses multiple inflammasome activation to regulate NASH progression by targeting ASC protein

Ren, L., Yang, H., Wang, H., Qin, S., Zhan, X., Li, H., Wei, Z., Fang, Z., Li, Q., Liu, T., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155758 · Cited by 18

Pathogenesis of Nonalcoholic Fatty Liver Disease

Machado, M. V., & Diehl, A. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-37591-7.00025-2 · Cited by 17

Exogenous Hydrogen Sulfide Alleviates-Induced Intracellular Inflammation in HepG2 Cells

Wang, Y., Li, J.-Y., Yu, Q., Liu, Q., Liao, Z., & Xiao, X. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0999-0149 · Cited by 17

2,3,5,4'‑tetrahydroxy‑stilbene‑2‑O‑β‑D‑glucoside attenuates methionine and choline‑deficient diet‑induced non‑alcoholic fatty liver disease

Han, M., Zhang, T., Gu, W., Yang, X., Zhao, R., & Yu, J. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6300 · Cited by 17

Molecular mechanisms of metabolic dysfunction-associated steatotic liver disease (MASLD): functional analysis of glucose and fructose metabolism pathways

Rabbani, N., & Thornalley, P. J. (2025) · Clinical Science · doi:10.1042/cs20257727 · Cited by 16

RNA adenosine deaminase (ADAR1) alleviates high-fat diet-induced nonalcoholic fatty liver disease by inhibiting NLRP3 inflammasome

Xiang, R., Liu, Y., Fan, L., Jiang, B., & Wang, F. (2022) · Laboratory Investigation · doi:10.1038/s41374-022-00805-8 · Cited by 16

An update: is there a relationship between H. pylori infection and nonalcoholic fatty liver disease? why is this subject of interest?

Chen, X., Peng, R., Peng, D., Xiao, J., Liu, D., & Li, R. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1282956 · Cited by 16

The Impact of Melatonin Supplementation and NLRP3 Inflammasome Deletion on Age-Accompanied Cardiac Damage

Sayed, R. K. A., Fernández‐Ortiz, M., Rahim, I., Fernández‐Martínez, J., Aranda‐Martínez, P., Rusanova, I., Martínez-Ruiz, L., Alsaadawy, R. M., Escames, G., & Acuña-Castroviejo, D. (2021) · Antioxidants · doi:10.3390/antiox10081269 · Cited by 17

Role of gut microbiota in the development of non-alcoholic fatty liver disease

Wang, X., Xia, J., & Jiang, C. (2019) · Liver Research · doi:10.1016/j.livres.2019.01.006 · Cited by 17

NOD-like receptors in the pathogenesis of metabolic (dysfunction)-associated fatty liver disease: Therapeutic agents targeting NOD-like receptors

Khanmohammadi, S., Ramos‐Molina, B., & Kuchay, M. S. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102788 · Cited by 15

Through regulation of the SIRT1 pathway plant sterol ester of α-linolenic acid inhibits pyroptosis thereby attenuating the development of NASH in mice

Han, H., Li, J., Tian, L., Pei, L., & Zheng, M. (2023) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2023.109408 · Cited by 15

Myeloid-specific ablation of Basp1 ameliorates diet-induced NASH in mice by attenuating pro-inflammatory signaling

Meng, Z., Zhou, L., Hong, S., Qiu, X., Chen, Z., Liu, T., Inoki, K., & Lin, J. D. (2023) · Hepatology · doi:10.1097/hep.0000000000000537 · Cited by 16

A guide to pathophysiology, signaling pathways, and preclinical models of liver fibrosis

Sultana, M., Islam, M. A., Khairnar, R., & Kumar, S. (2025) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2024.112448 · Cited by 15

Molecular and ultrastructure study of endoplasmic reticulum stress in hepatic steatosis: role of hepatocyte nuclear factor 4α and inflammatory mediators

El‐khair, S. M. A., Ghoneim, F. M., Shabaan, D. A., & Elsamanoudy, A. Z. (2019) · Histochemistry and Cell Biology · doi:10.1007/s00418-019-01823-2 · Cited by 15

Dietary lycopene attenuates cigarette smoke-promoted nonalcoholic steatohepatitis by preventing suppression of antioxidant enzymes in ferrets

Rakic, J. M., Liu, C., Veeramachaneni, S., Wu, D., Paul, L., Ausman, L. M., & Wang, X. (2021) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2021.108596 · Cited by 15

Dynamic co-expression modular network analysis in nonalcoholic fatty liver disease

Zheng, J., Wu, H., Zhang, Z., & Yao, S. (2021) · Hereditas · doi:10.1186/s41065-021-00196-8 · Cited by 15

Inhibition of hepatic NLRP3 inflammasome ameliorates non-alcoholic steatohepatitis/hepatitis B - induced hepatic injury

Chen, F., Liu, Y., Li, Q., & Wang, F. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.102056 · Cited by 14

Mitochondria at the Crossroads: Linking the Mediterranean Diet to Metabolic Health and Non-Pharmacological Approaches to NAFLD

Mercurio, G., Giacco, A., Scopigno, N., Vigliotti, M., Goglia, F., Cioffi, F., & Silvestri, E. (2025) · Nutrients · doi:10.3390/nu17071214 · Cited by 16

Pro-Inflammatory Interleukin-18 is Associated with Hepatic Steatosis and Elevated Liver Enzymes in People with HIV Monoinfection

Sim, J. H., Sherman, J. B., Stanley, T. L., Corey, K. E., Fitch, K. V., Looby, S. E. D., Robinson, J. A., Lu, M. T., Burdo, T. H., & Lo, J. (2020) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2020.0177 · Cited by 14

NLRP3 as a sensor of metabolism gone awry

Neuwirt, E., Gorka, O., Saller, B. S., Groß, C. J., Madl, T., & Groß, O. (2021) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2021.03.009 · Cited by 13

Obeticholic acid improves hepatic steatosis and inflammation by inhibiting NLRP3 inflammasome activation.

Yang, Z., Liu, F., Liu, P., Guo, W.-J., Xiong, G.-Y., Pan, H., & Wei, L. (2017) · PubMed Central · Cited by 14

Chrysin prevents inflammation-coinciding liver steatosis via AMPK signalling

Gao, C., Zhang, H., Nie, L., He, K., Li, P., Wang, X., Zhang, Z., Xie, Y., Li, S., Liu, G., et al. (2023) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgad041 · Cited by 13

Vitamin D Mitigates Hepatic Fat Accumulation and Inflammation and Increases SIRT1/AMPK Expression in AML-12 Hepatocytes

Chang, E. (2024) · Molecules · doi:10.3390/molecules29061401 · Cited by 19

Inflammatory and Non-Inflammatory Mechanisms Controlling Cirrhosis Development

Sánchez, P. S., Rigual, M. D. M., & Djouder, N. (2021) · Cancers · doi:10.3390/cancers13205045 · Cited by 13

The Potential Effect of Chinese Herbal Formula Hongqijiangzhi Fang in Improving NAFLD: Focusing on NLRP3 Inflammasome and Gut Microbiota

Shu, L., Zhang, Y., Deng, Y., He, Y., Liang, Y., Liang, Z., Chen, Y., Tang, K., Chen, R., & Yang, Q. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/5378961 · Cited by 13

NLRP3 deficiency did not attenuate NASH development under high fat calorie diet plus high fructose and glucose in drinking water

Zhu, L., Liu, C., Li, Z.-R., Niu, C., & Wu, J. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00535-3 · Cited by 13

Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis

Bernhard, J., Galli, L., Speidl, W. S., & Krychtiuk, K. A. (2025) · Current Cardiology Reports · doi:10.1007/s11886-024-02185-5 · Cited by 18

High uric acid exacerbates nonalcoholic steatohepatitis through NLRP3 inflammasome and gasdermin D-mediated pyroptosis

Xu, Z.-X., Tang, C., Song, X., Liu, Z.-N., Zhou, J., Shi, Q., Yu, C.-H., & Xu, C. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110249 · Cited by 14

Btk knockout attenuates the liver inflammation in STZ-induced diabetic mice by suppressing NLRP3 inflammasome activation

Li, Y., Zhao, J., Wu, Y., & Xia, L. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.02.094 · Cited by 12

Pharmacological effects of Chinese medicine modulating NLRP3 inflammasomes in fatty liver treatment

Liu, T., Xu, G., Liang, L., Xiao, X., Zhao, Y., & Bai, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.967594 · Cited by 12

Significance of elevated serum and hepatic NOD-like receptor pyrin domain containing 3 (NLRP3) in hepatitis C virus-related liver disease

Aggan, H. E., Mahmoud, S., Deeb, N. E., Eleishi, I., & El-Shendidi, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-22022-5 · Cited by 12

Characterization of liver changes in ZSF1 rats, an animal model of metabolic syndrome

Borges‐Canha, M., Portela-Cidade, J. P., Conceição, G., Sousa-Mendes, C., Leite, S., Fontoura, D., Moreira‐Gonçalves, D., Falcão‐Pires, I., Lourenço, A. P., Leite-Moreira, A. F., et al. (2017) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2017.4575/2016 · Cited by 12

Elucidation of the anti-arthritic mechanism of Guizhi-Shaoyao-Zhimu decoction by reshaping circadian rhythm

He, X., Li, R., He, X., He, F., Xiao, Y., Chen, X., Lai, Y., Guo, W., Liu, P., Cai, X., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107787 · Cited by 11

The role and mechanism of pyroptosis and potential therapeutic targets in non-alcoholic fatty liver disease (NAFLD)

Li, S., Liu, A.-B., Yu, Y., & Ma, J.-H. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1407738 · Cited by 12

Underrated enemy – from nonalcoholic fatty liver disease to cancers of the gastrointestinal tract

Derra, A., Bator, M., Menżyk, T., & Kukla, M. (2018) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2018.75955 · Cited by 11

Foresight regarding drug candidates acting on the succinate–GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment

Liang, C., Li, J., Tian, B., Tian, L., Liu, Y., Li, J., Xin, L., Wang, J., Fu, C., Shi, Z., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112298 · Cited by 12

Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases

Gallego‐Durán, R., Montero‐Vallejo, R., Maya‐Miles, D., Lucena, A., Martı́n, F., Ampuero, J., & Romero‐Gómez, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.667354 · Cited by 12

Free radicals, antioxidants, nuclear factor-E2-related factor-2 and liver damage

Ramos‐Tovar, E., & Muriel, P. (2022) · Vitamins and hormones · doi:10.1016/bs.vh.2022.09.006 · Cited by 11

Pharmacology of a Potent and Novel Inhibitor of the NOD-Like Receptor Pyrin Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis

Povero, D., Lazić, M., McBride, C., Ambrus-Aikelin, G., Stansfield, R. K., Johnson, C. D., Santini, A. M., Pranadinata, R. F., McGeough, M. D., Stafford, J. A., et al. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.001639 · Cited by 11

The NALP3 inflammasome is required for collagen synthesis via the NF‑κB pathway

Kuang, J., Xie, M., & Wei, X. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3404 · Cited by 11

Serum soluble sialic acid‐binding immunoglobulin‐like lectin‐7 concentration as an indicator of liver macrophage activation and advanced fibrosis in patients with non‐alcoholic fatty liver disease

Sakamoto, Y., Yoshio, S., Doi, H., Kawai, H., Shimagaki, T., Mori, T., Matsuda, M., Aoki, Y., Osawa, Y., Yoshida, Y., et al. (2019) · Hepatology Research · doi:10.1111/hepr.13464 · Cited by 11

Exercising in the COVID-19 era: implications in non-alcoholic fatty liver disease (NAFLD)

O’Gorman, P., & Norris, S. (2021) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2020-000568 · Cited by 11

Hepatic Macrophages as Targets for the MSC-Based Cell Therapy in Non-Alcoholic Steatohepatitis

Kholodenko, I. V., & Yarygin, K. N. (2023) · Biomedicines · doi:10.3390/biomedicines11113056 · Cited by 14

Role of MMP-2 and MMP-9 in the Relationship between Inflammation, Fibrosis, and Apoptosis during Progression of Non-Alcoholic Fatty Liver Disease and Diagnostic Significance of Plasma Levels of Their Active Forms

Валерьевна, К. И., Topchieva, L., Дуданова, О. П., & Shipovskaya, A. A. (2024) · Biochemistry (Moscow) · doi:10.1134/s0006297924110130 · Cited by 11

Dehydrotrametenolic acid methyl ester, a triterpenoid of Poria cocos, alleviates non-alcoholic steatohepatitis by suppressing NLRP3 inflammasome activation via targeting Caspase-1 in mice

Xia, L.-Y., Yu, N.-R., Huang, S., Qu, H. Y., Li, Q., Zhao, Q., & Leng, Y. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01569-9 · Cited by 10

ASIC1a inhibits cell pyroptosis induced by acid‐induced activation of rat hepatic stellate cells

Li, J., Kong, L., Huang, H., Luan, S., Jin, R., & Wu, F. (2020) · FEBS Open Bio · doi:10.1002/2211-5463.12850 · Cited by 10

Assessment of hepatic fatty acids during non-alcoholic steatohepatitis progression using magnetic resonance spectroscopy

Xavier, A., Zacconi, F. C. M., Santana-Romo, F. M., Eykyn, T. R., Lavín, B., Phinikaridou, A., Botnar, R. M., Uribe, S. A., Oyarzún, J. E., Cabrera, D., et al. (2021) · Annals of Hepatology · doi:10.1016/j.aohep.2021.100358 · Cited by 10

Capillin protects against non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation and oxidative stress

Li, B., Wang, R., Wang, L., Zhang, G., & Zhang, Y. (2021) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2021.1984520 · Cited by 10

Burden and Predictors of Non-Alcoholic Fatty Liver Disease in a Retrospective Cohort of Patients With Crohn’s Disease

Abomhya, A., Mahmoodurrahman, M., Ayaz, S., Hamad, H. E., & KHAN, F. R. (2022) · Gastroenterology Research · doi:10.14740/gr1509 · Cited by 10

Inflammasome-Mediated Cytokines: A Key Connection between Obesity-Associated NASH and Liver Cancer Progression

da Cruz, N. S., Pasquarelli-do-Nascimento, G., Oliveira, A. C. P. E., & Magalhães, K. G. (2022) · Biomedicines · doi:10.3390/biomedicines10102344 · Cited by 10

Common Pathogenetic Pathways of Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

Giannopoulos, C., Tzima, I. G., Tentolouris, N., & Vasileiadis, I. (2023) · Current Diabetes Reviews · doi:10.2174/1573399819666230216112032 · Cited by 12

Obesity and Viral Infections

Jaisinghani, P., & Kumar, R. B. (2023) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2023.03.012 · Cited by 10

Novel insights into metabolic‐associated steatotic liver disease preclinical models

Montero‐Vallejo, R., Maya‐Miles, D., Ampuero, J., Martı́n, F., Romero‐Gómez, M., & Gallego‐Durán, R. (2024) · Liver International · doi:10.1111/liv.15830 · Cited by 10

A Toolbox of Potential Immune-Related Therapies for Inflammatory Cardiomyopathy

Elsanhoury, A., Tschöpe, C., & Linthout, S. V. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-10025-4 · Cited by 10

Dual role of pyroptosis in liver diseases: mechanisms, implications, and therapeutic perspectives

Yang, S., Zou, Y., Zhong, C., Zhou, Z., Peng, X., & Tang, C. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1522206 · Cited by 9

Intestinal Bacterial Dysbiosis and Liver Fibrosis in Mice Through Gut‐Liver Axis and NLRP3 Inflammatory Pathway Caused by Fine Particulate Matter

Fu, P., Zhang, M., Bai, L., Chen, S., Chen, W., Li, Z., Yue, J., Dong, C., & Li, R. (2025) · Journal of Applied Toxicology · doi:10.1002/jat.4767 · Cited by 9

Interleukin-1β in circulating mononuclear cells predicts steatotic liver disease improvement after weight loss in subjects with obesity and prediabetes or type 2 diabetes

Simeone, P., Costantino, S., Liani, R., Tripaldi, R., Castelnuovo, A. F. D., Tartaro, A., Mengozzi, A., Cosentino, F., Cipollone, F., Consoli, A., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02706-8 · Cited by 12

Activation of mitophagy by rapamycin eliminated the accumulation of TDP-43 on mitochondrial and promoted the resolution of carbon tetrachloride-induced liver fibrosis in mice

Yong, H., Shan, S., Wang, S., Liu, Z., Liu, Z., Zhang, C., Yang, Y., Huang, Z., & Song, F. (2022) · Toxicology · doi:10.1016/j.tox.2022.153176 · Cited by 9

17β-Estradiol transcriptionally modulates Nlrp1 and Nlrp3 inflammasomes in gonadectomized rats with inflammation

Gómez‐López, M., Domínguez‐López, A., Abarca‐Rojano, E., Hernández, S. R., Martínez–Godínez, M. D. L. Á., Miliar-García, Á., & Rodríguez, R. C. (2015) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2015.1059439 · Cited by 9

NLRP3 sparks the Greek fire in the war against lipid‐related diseases

Jiang, S., Xiao, H., Wu, Z. B., Yang, Z. P., Ding, B., Jin, Z., & Yang, Y. (2020) · Obesity Reviews · doi:10.1111/obr.13045 · Cited by 9

The interplay between host cellular and gut microbial metabolism in NAFLD development and prevention

Yu, S., & Xu, L. (2021) · Journal of Applied Microbiology · doi:10.1111/jam.14992 · Cited by 9

Emerging Therapies for Alcoholic Hepatitis

Han, M. A. T., & Pyrsopoulos, N. (2021) · Clinics in Liver Disease · doi:10.1016/j.cld.2021.03.006 · Cited by 9

The study of routine laboratory factors in children with mycoplasma pneumoniae pneumonia: serum uric acid may have anti‐inflammatory effect

Pan, C., Chen, Y., Wang, S., Li, M., & Qu, S. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24026 · Cited by 8

Lansoprazole prevents the progression of liver fibrosis in non-alcoholic steatohepatitis model rats

Nishi, T., Yamamoto, Y., Yamagishi, N., Iguchi, M., Tamai, H., Ito, T., Tsuruo, Y., Ichinose, M., Kitano, M., & Ueyama, T. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12870 · Cited by 9

Piperine alleviates nonalcoholic steatohepatitis by inhibiting NF-κB-mediated hepatocyte pyroptosis

Ran, S., Song, L., Yang, H. S., Yu, J., Zhen, Y.-H., & Liu, Q. (2024) · PLoS ONE · doi:10.1371/journal.pone.0301133 · Cited by 8

NLRP3 Inflammasome Activation Is Involved in Geniposide‐Induced Hepatotoxicity

Liu, Y., Liu, B., Shi, M., Ye, T., & Li, H. (2025) · Mediators of Inflammation · doi:10.1155/mi/4112856 · Cited by 8

Pathogenesis of NAFLD and NASH

Maher, J. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-20538-0_4 · Cited by 8

The Inhibition of Bruton Tyrosine Kinase Alleviates Acute Liver Failure via Downregulation of NLRP3 Inflammasome

Ye, B., Chen, S., Guo, H., Zheng, W., Lou, G., Liang, X., Liu, Y., Zhou, C., & Zheng, M. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2001323 · Cited by 8

Protein-protein interactions and related inhibitors involved in the NLRP3 inflammasome pathway

Ma, Z., Jiang, C., & Xu, L. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.09.003 · Cited by 8

Biochemical and hematological reference intervals in rhesus and cynomolgus macaques and implications for vaccine and drug development

Yan, X., Cerveira, R. A., Ols, S., Lenart, K., Hellgren, F., Miranda, M. C., Engstrand, O., Reinhardt, A., Eriksson, B., & Loré, K. (2025) · Lab Animal · doi:10.1038/s41684-025-01547-y · Cited by 7

Insights of gut-liver axis in hepatic diseases: Mechanisms, clinical implications, and therapeutic potentials

Jeyaraman, N., Jeyaraman, M., Mariappan, T., Muthu, S., Ramasubramanian, S., Sharma, S., Santos, G. S., da Fonseca, L. F., & Lana, J. F. (2024) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v15.i6.98146 · Cited by 7

Role of ER Stress in Inflammasome Activation and Non-Alcoholic Fatty Liver Disease Progression

Lebeaupin, C., & Vallée, D. (2016) · Single Cell Biology · doi:10.4172/2168-9431.1000140 · Cited by 7

The Impact of the NLRP3 Pathway in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease

Sheriff, L., & Lalor, P. F. (2021) · Livers · doi:10.3390/livers1020007 · Cited by 7

Immunometabolic factors contributing to obesity-linked hepatocellular carcinoma

Akl, M. G., & Widenmaier, S. B. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1089124 · Cited by 6

NLRP3 Deficiency in Nonimmune Cells Averts Obesity-Induced Fatty Liver Disease

Grigg, L. M., Shrkihe, B. A., Efimova, I., Solodeev, I., Shteingard, Y., Shani, N., Zvibel, I., & Varol, C. (2023) · Laboratory Investigation · doi:10.1016/j.labinv.2023.100308 · Cited by 6

Natural products targeting NLRP3 inflammasome for metabolic dysfunction-associated fatty liver disease: the known unknowns

Meng, J., Wang, Q., Wang, H., Shen, X., Qin, T., Zhao, W. H., Li, H., & Yuan, Z. (2025) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(25)60970-8 · Cited by 5

A new liver-targeted agonist of thyroid hormone receptor beta resmetirom in treating MASLD/MASH: From mechanism to therapy

Liu, M., Ma, Y., Cheang, W. S., Su, Z., & Xu, S. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.011 · Cited by 8

Downregulation of Setdb2 promotes alternative activation of macrophages via the PI3K/Akt pathway to attenuate NAFLD after sleeve gastrectomy

Yu, T., Wang, L., Cheng, Y., Zhang, Y., Zhu, J., Zhang, G., & Hu, S. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150264 · Cited by 5

Macronutrient Modulation in Metabolic Dysfunction-Associated Steatotic Liver Disease—the Molecular Role of Fatty Acids compared with Sugars in Human Metabolism and Disease Progression

Mullin, S. M., Kelly, A. J., Chathail, M. B. N., Norris, S., Shannon, C. E., & Roche, H. M. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100375 · Cited by 10

Fluorofenidone attenuates choline-deficient, l-amino acid-defined, high-fat diet-induced metabolic dysfunction-associated steatohepatitis in mice

Zhang, J., Wang, Q., Zhou, N., Liu, J., Tao, L., Peng, Z., Hu, G., Wang, H., Fu, L., & Peng, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-94401-7 · Cited by 5

Progress in the Correlation Between Inflammasome NLRP3 and Liver Fibrosis

Sun, M., Zhang, Y., Guo, A., Xia, Z., & Peng, L. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2023.00231 · Cited by 5

From complement to complosome in non‐alcoholic fatty liver disease: When location matters

Nguyen, V., Hughes, T. R., & Zhou, Y. (2023) · Liver International · doi:10.1111/liv.15796 · Cited by 6

Custom RT-qPCR-array for glaucoma filtering surgery prognosis

Rodríguez-Agirretxe, I., García, I., Soria, J. M., Suárez, T., & Acera, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174559 · Cited by 4

Molecular Basis for Pathogenesis of Steatohepatitis: Contemporary Understanding and New Insights

Parkash, O., & Saeed, S. (2018) · InTech eBooks · doi:10.5772/intechopen.71405 · Cited by 5

Chronological activation of the NLRP3 inflammasome/pyroptosis pathway in the progression from metabolic dysfunction-associated fatty liver disease to hepatocellular carcinoma

Márquez-Quiroga, L. V., Vargas-Pozada, E. E., Cardoso-Lezama, I., Ramos‐Tovar, E., Vásquez-Garzón, V. R., Piña‐Vázquez, C., Villa‐Treviño, S., Arellanes‐Robledo, J., & Muriel, P. (2025) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2025.2524749 · Cited by 4

Hepatic SPARC Expression Is Associated with Inflammasome Activation during the Progression of Non-Alcoholic Fatty Liver Disease in Both Mice and Morbidly Obese Patients

Onorato, A. M., Mauriz, L. L., Bayo, J., Fiore, E. J., Cantero, M. J., Bueloni, B., García, M. G., Lagües, C., Martinez‐Duartez, P., Menaldi, G., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914843 · Cited by 4

The Coptidis Rhizoma and Bovis Calculus herb pair attenuates NASH and inhibits the NLRP3 inflammasome activation

Xu, T., Chen, J., Shao, Q., Ji, J., Wang, Q., Ma, C., Wang, X., & Cheng, F. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34718 · Cited by 4

ER stress aggravates NOD1-mediated inflammatory response leading to impaired nutrient metabolism in hepatoma cells

Gulzar, F., Chhikara, N., Kumar, P., Ahmad, S., Yadav, S., Gayen, J. R., & Tamrakar, A. K. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150827 · Cited by 5

NLRP3 Inflammasome Activation in Myeloid Cells Is Crucial for Liver Inflammation and Fibrosis in Murine Steatohepatitis

Kaufmann, B. K., Reca, A., Leszczynska, A., Kim, A. D., Booshehri, L. M., Friess, H., Hartmann, D., Broderick, L., Hoffman, H., & Feldstein, A. E. (2022) · HPB · doi:10.1016/j.hpb.2022.05.454

NLRP3 inflammasome activation in leucocytes drives hepatic stellate cell activation and fibrosis in non-alcoholic steatohepatitis

Kaufmann, B. K., Kui, L., Reca, A., Leszczyńska, A. N., Kim, A. D., Booshehri, L. M., Wree, A., Friess, H., Hüser, N., Hartmann, D., et al. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0042-1754729

Cell-specific Deletion of NLRP3 Inflammasome Identifies Myeloid Cells as Key Drivers of Liver Inflammation and Fibrosis in Murine Steatohepatitis

Kaufmann, B., Kui, L., Reca, A., Leszczynska, A., Kim, A. D., Booshehri, L. M., Wree, A., Friess, H., Hartmann, D., Broderick, L., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.06.007 · Cited by 51

The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment

Yu, L., Hong, W., Lu, S., Li, Y., Guan, Y., Weng, X., & Feng, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.780496 · Cited by 126

Hepatic nucleotide binding oligomerization domain‐like receptors pyrin domain‐containing 3 inflammasomes are associated with the histologic severity of non‐alcoholic fatty liver disease

Mitsuyoshi, H., Yasui, K., Hara, T., Taketani, H., Ishiba, H., Okajima, A., Seko, Y., Umemura, A., Nishikawa, T., Yamaguchi, K., et al. (2017) · Hepatology Research · doi:10.1111/hepr.12883 · Cited by 32